Skip to main content

Esperoct FDA Approval History

Last updated by Judith Stewart, BPharm on May 19, 2020.

FDA Approved: Yes (First approved February 19, 2019)
Brand name: Esperoct
Generic name: turoctocog alfa pegol
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Hemophilia A

Esperoct (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for the treatment of adults and children with hemophilia A.

Development Timeline for Esperoct

DateArticle
Feb 19, 2019Approval  FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.